ACE2 and diabetes mellitus: Clinical investigations have revealed that patients with cardiac diseases, hypertension, or diabetes who are administered with angiotensin-converting enzyme 2 (ACE2)-enhancing drugs including inhibitors and blockers exhibited elevated expression of ACE2; thus, the risk of getting the SARS-CoV-2 infection increased manifolds in such patients (Fang et al., 2020).